Perhaps the biggest move that Lykos has taken in the wake of this fallout, however, is the hiring of a former Johnson & Johnson executive named David Hough to lead the company’s continued clinical development program and engagement with the FDA. Hough was previously the Vice President of Research and Development at J&J Innovative Medicine, and served in leadership roles over 17 years. He was responsible for leading the program that brought Spravato, Johnson & Johnson’s patented esketamine nasal spray, to the market. Hough is also a graduate of West Point, and has served both as an Army officer and Army psychiatrist for ten years in different military hospitals.
Read more at Doubleblind
Big Pharma Executive Is Now Leading the Movement to Legalize MDMA
